Table 3. Odds ratio (95% CI) for poor functional outcome at 3 months by quartiles, 1-SD change and optimal cut-off value in alkaline phosphatase levels.
| ALP Quartiles, U/L |
1-SD increase in ALP levels |
ALP (≥ 288) vs. ALP (＜288) |
||||
|---|---|---|---|---|---|---|
|
Q1 (≤ 192) ( n = 374) |
Q2 (193–238) ( n = 371) |
Q3 (239–296) ( n = 368) |
Q4 (≥ 297) ( n = 371) |
|||
| Model 1 | 1.00 | 1.04 (0.70–1.55) | 1.64 (1.12–2.41) | 1.98 (1.36–2.90) | 1.30 (1.11–1.56) | 1.88 (1.42-2.48) |
| Model 2 | 1.00 | 1.01 (0.66–1.52) | 1.62 (1.10–2.42) | 1.80 (1.21–2.68) | 1.21 (1.02–1.49) | 1.81 (1.35-2.42) |
| Model 3 | 1.00 | 1.06 (0.70–1.60) | 1.72 (1.16–2.54) | 1.91 (1.29–2.83) | 1.31 (1.09–1.61) | 1.76 (1.32-2.33) |
Model 1: age, sex, body mass index, daily alcohol intake, current smoking, comorbidities (hypertension, diabetes mellitus, dyslipidaemia, chronic kidney disease and atrial fibrillation), previous stroke, previous ischaemic heart disease, National Institutes Health Stroke Scale, ALP levels (quartiles range or 1-SD increase).
Model 2; the other blood laboratory findings were added to model 1.
Model 3: Calculated scores (CONUT, GNRI, NLR, PLR, and CAR) were added to model 1.
ALP, alkaline phosphatase; CONUT, Controlling Nutritional Status; GNRI, Geriatric Nutritional Risk Index; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; CAR, C reactive protein-to-albumin ratio